Conotoxins: Drug Candidates from Cone Snails
Venom-Derived Peptides
1,000,000+ estimated unique peptides
Approximately 800 species of cone snails collectively produce an estimated 1 million or more unique venom peptides, yet less than 0.1% have been characterized. One conotoxin, omega-conotoxin MVIIA from Conus magus, became ziconotide (Prialt), an FDA-approved non-opioid pain drug 1,000 times more potent than morphine.
Smallwood & Bhatt, Toxicon X, 2021
Smallwood & Bhatt, Toxicon X, 2021
View as imageCone snails are predatory marine gastropods that hunt fish, worms, and other mollusks by injecting venom through a harpoon-like tooth. Their venom is not a single toxin but a complex cocktail of 100-200 distinct peptides per species, each evolved to target a specific molecular receptor in the prey's nervous system with extraordinary selectivity and potency. With approximately 800 cone snail species, each producing a unique venom composition, the total conotoxin library represents one of the largest untapped reservoirs of pharmacologically active peptides in nature. Smallwood and Bhatt (2021) estimated that over 1 million unique conotoxins exist across all species, of which less than 0.1% have been structurally and functionally characterized.[1] For how conotoxins fit into the broader landscape of venom-derived peptide research, see the pillar article.
Key Takeaways
- Cone snails produce an estimated 1 million+ unique venom peptides across approximately 800 species, with less than 0.1% characterized (Smallwood & Bhatt, Toxicon X, 2021)
- Ziconotide (omega-conotoxin MVIIA from Conus magus), approved by the FDA in 2004, is a non-opioid analgesic approximately 1,000 times more potent than morphine, delivered intrathecally for severe chronic pain
- Conotoxins target ion channels (sodium, potassium, calcium), nicotinic acetylcholine receptors, GPCR receptors, and neurotransmitter transporters with extreme selectivity, making them molecular tools for neuroscience and drug leads
- Alpha-conotoxin Vc1.1, targeting nicotinic acetylcholine receptors, was in clinical trials for neuropathic pain before being discontinued due to efficacy concerns (Tae et al., 2025)
- Cone snail venom-inspired somatostatin receptor 4 agonists represent a new approach using conotoxin scaffolds to target non-traditional pain pathways (Bjorn-Yoshimoto et al., 2025)
- Machine learning is accelerating conotoxin classification and prediction of function from sequence, potentially unlocking the 99.9% of conotoxins that remain uncharacterized (Li et al., 2025)
Ziconotide: The Proof of Concept
The story of conotoxins in medicine begins with Baldomero Olivera's laboratory at the University of Utah in the 1980s. Olivera's team isolated omega-conotoxin MVIIA from the venom of Conus magus (the magician's cone snail), a 25-amino acid peptide that blocks N-type voltage-gated calcium channels (Cav2.2) with high selectivity. Blocking these channels in the dorsal horn of the spinal cord interrupts pain signal transmission without activating opioid receptors, a non-addictive mechanism of action.
The synthetic version, ziconotide (branded as Prialt), was approved by the FDA in December 2004 for the management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Its potency is remarkable: approximately 1,000 times more potent than morphine on a molar basis. The critical limitation is delivery. Ziconotide must be administered intrathecally (directly into the spinal fluid) via an implanted pump because it cannot cross the blood-brain barrier and is rapidly degraded if given orally or intravenously. The intrathecal delivery requirement restricts its use to patients with the most severe, refractory pain, typically end-stage cancer pain or severe neuropathic conditions.
Ziconotide's approval validated the principle that venom peptides can become precision medicines. It also revealed the core challenge: delivery. Nearly every conotoxin drug candidate since has struggled with the same problem. These peptides evolved to be injected directly into prey tissue, not to survive the human digestive tract or bloodstream.
The Conotoxin Pharmacological Toolkit
What makes conotoxins exceptional as drug leads is their target selectivity. Unlike most small-molecule drugs, which typically hit multiple related receptors (causing side effects), individual conotoxins have evolved to distinguish between closely related receptor subtypes. This selectivity arises from their constrained three-dimensional structures, stabilized by multiple disulfide bonds that lock the peptide into a precise shape complementary to a single receptor binding site.
Conotoxins are classified by their molecular targets:
Omega-conotoxins block voltage-gated calcium channels. Ziconotide (omega-MVIIA) targets Cav2.2 (N-type). Other omega-conotoxins target different calcium channel subtypes with varying selectivity profiles.
Alpha-conotoxins block nicotinic acetylcholine receptors (nAChRs). These are the most extensively studied family after omega-conotoxins. Tae et al. (2025) elucidated the molecular determinants of selectivity and potency of alpha-conotoxin Vc1.1 for human nicotinic acetylcholine receptor subtypes, work that informs the design of next-generation nAChR-targeted analgesics.[2] Alpha-Vc1.1 entered clinical trials for neuropathic pain but was discontinued when efficacy endpoints were not met, illustrating the gap between receptor-level potency and clinical efficacy.
Mu-conotoxins block voltage-gated sodium channels, the same targets as local anesthetics like lidocaine, but with far greater subtype selectivity.
Kappa-conotoxins block voltage-gated potassium channels. The potassium channel KV1.3 has been identified as a therapeutic target for autoimmune diseases, and venom-derived peptides targeting this channel are under investigation.[3]
Chi-conotoxins target norepinephrine transporters, providing leads for pain and psychiatric conditions.
Coulter-Parkhill et al. (2021) reviewed the therapeutic potential of peptides derived from animal venoms broadly, noting that cone snail venoms represent the richest source of ion channel-targeting peptides in nature, with applications extending beyond pain to include cardiovascular disease, epilepsy, and autoimmune conditions.[4]
New Directions: Beyond Ion Channels
The most recent conotoxin research has moved beyond traditional ion channel targets.
Bjorn-Yoshimoto et al. (2025) reported cone snail venom-inspired somatostatin receptor 4 (SSTR4) agonists as new drug leads for peripheral analgesia. Rather than blocking ion channels, these peptides activate an inhibitory GPCR that suppresses pain signaling through a different mechanism entirely. The approach uses the conotoxin structural scaffold (the cysteine-rich framework that provides stability and receptor selectivity) while directing it toward a non-traditional target. This represents a conceptual shift from using conotoxins as-is to using conotoxin architecture as a design template for novel drugs.[5]
Jergova et al. (2021) identified cannabinoid receptor agonists derived from Conus venoms that alleviate pain-related behavior in rats. The finding that cone snail venom contains peptides that activate cannabinoid receptors, in addition to the expected ion channel toxins, expanded the known target space of conotoxins beyond the neuromuscular junction.[6]
Margiotta et al. (2022) reviewed novel therapeutic opportunities from Conus regius-derived conotoxins, identifying peptides with anti-inflammatory, antimicrobial, and neuroprotective activities that go beyond the classical analgesic applications.[7]
Fouda et al. (2021) conducted a proteomic analysis of Red Sea Conus taeniatus venom, revealing potential biological applications including antimicrobial and anticancer peptides from a species not previously studied pharmacologically. This geographic exploration underscores how much of the conotoxin library remains untapped: most research has focused on a handful of species from the Indo-Pacific, while hundreds of species from less-studied regions remain pharmacologically unexplored.[8]
The Bioinformatics Revolution
The sheer scale of conotoxin diversity, over a million estimated peptides, makes traditional one-at-a-time characterization impractical. Bioinformatics and machine learning are now the primary tools for navigating this chemical space.
Li et al. (2025) published a comprehensive review of conotoxin classification, prediction, and future directions in bioinformatics. Machine learning models can now predict a conotoxin's likely molecular target from its amino acid sequence alone, enabling researchers to prioritize the most promising candidates for experimental testing from the millions of possibilities. The approach integrates cysteine pattern recognition (the arrangement of disulfide bonds that defines conotoxin families) with deep learning models trained on known conotoxin-target relationships.[9]
Bibi et al. (2025) advanced this further with cysteine pattern barcoding-based dataset filtration that enhances machine learning-assisted interpretation of conotoxin function. The method treats the cysteine framework as a barcode that encodes structural and functional information, allowing computational screening of novel sequences against known pharmacological profiles.[10]
Wiere et al. (2022) demonstrated the bioengineering approach: synthesizing a novel alpha-conotoxin from milked venom of Conus obscurus, showing that conotoxins can be produced recombinantly at scale rather than extracted from limited venom supplies.[11] Scalable production is essential for any conotoxin to transition from laboratory curiosity to clinical drug candidate.
The Delivery Challenge
The central obstacle to conotoxin drug development remains delivery. These peptides are typically 10-40 amino acids long, stabilized by 2-4 disulfide bonds, and highly specific to their molecular targets. They are also rapidly degraded by digestive enzymes, poorly absorbed through the gut lining, and unable to cross the blood-brain barrier in most cases.
Ziconotide's intrathecal delivery requirement is not a design choice. It is a concession to biological reality. For conotoxins to become broadly useful medicines, one of several delivery problems must be solved: oral bioavailability (through cyclization, D-amino acid substitution, or formulation technology), intranasal delivery to bypass the blood-brain barrier, transdermal patches for peripheral targets, or prodrug strategies that protect the peptide until it reaches its target.
The broader field of venom-derived peptides faces the same delivery challenges, and solutions developed for one venom peptide class may transfer to others. Scorpion venom peptides and snake venom peptides each have their own delivery and stability profiles that inform the broader venom-to-drug pipeline.
Hsiao et al. (2024) described a molecular display approach for discovery of novel therapeutic peptides from the animal meta-venome, a strategy that screens vast libraries of venom peptide sequences for drug-like properties including stability and cell permeability, potentially identifying conotoxins that naturally have better pharmacokinetic profiles.[12]
The Evolutionary Logic of Conotoxin Diversity
Understanding why cone snails produce such extraordinary peptide diversity illuminates why conotoxins are so valuable as drug leads.
Each cone snail species occupies a specific ecological niche: some hunt fish, some hunt worms, some hunt other mollusks. The venom composition is optimized for the prey's specific nervous system. Fish-hunting species like Conus geographus produce venoms dominated by peptides targeting vertebrate ion channels and receptors, making these venoms directly relevant to mammalian (and human) pharmacology. Worm-hunting species produce peptides targeting invertebrate-specific receptors, which are less useful for human medicine but reveal novel receptor pharmacology.
Within a single species, venom composition varies between individuals, between geographic populations, and even between successive venom extractions from the same snail. This intraspecific variation means that even well-studied species may harbor undiscovered peptide variants with distinct pharmacological properties. A single cone snail is, in effect, a combinatorial chemistry laboratory running continuous evolutionary experiments on peptide-receptor interactions.
The disulfide-rich framework that characterizes conotoxins (typically 2-4 disulfide bonds in a peptide of 10-40 amino acids) provides a scaffold that is both structurally rigid and evolutionarily plastic. The cysteine residues that form the disulfide bonds remain conserved (maintaining the overall fold), while the intervening residues mutate rapidly (changing receptor selectivity). This architecture allows evolution to sample enormous receptor-binding diversity while maintaining the structural stability needed for a functional venom component. Drug designers have recognized this as an ideal platform: a naturally optimized scaffold that can be rationally modified to alter target selectivity, potency, or pharmacokinetics.
The conservation implications are also worth noting. As coral reef ecosystems decline globally, cone snail habitats are being lost before their venom peptides can be characterized. The pharmacological diversity disappearing with each reef degradation event is incalculable. Bioinformatic approaches that predict peptide function from genomic data provide a partial solution, allowing venom gland transcriptomes to be preserved and analyzed even when live specimens are no longer available.
Where Conotoxin Research Stands
The conotoxin field exists in a state of enormous potential and limited clinical translation. One drug (ziconotide) has been approved. Several candidates have entered and exited clinical trials. The vast majority of the estimated million-plus conotoxins remain uncharacterized. Machine learning and proteomic technologies are now capable of screening this diversity at a rate that was impossible a decade ago, but the fundamental delivery problem persists.
The field's future likely lies not in finding the next ziconotide but in using conotoxin scaffolds as design templates for engineered peptides with improved pharmacokinetic properties. The selectivity that evolution produced, a peptide that hits one calcium channel subtype while ignoring all others, is exactly what drug designers want. The challenge is repackaging that selectivity into a form that the human body can absorb, distribute, and tolerate.
For the broader venom-derived peptide field, conotoxins represent both the greatest success story (ziconotide) and the clearest illustration of why venom peptides are so difficult to develop as drugs: their natural delivery mechanism (injection through a harpoon) does not translate to clinical delivery.
The timeline from venom characterization to approved drug is also instructive. Omega-conotoxin MVIIA was first isolated in the early 1980s. Ziconotide was approved in 2004. That 20-year development cycle, for the most promising conotoxin ever identified, underscores the difficulty of translating venom peptides into clinical therapeutics. The candidates currently in the pipeline, targeting somatostatin receptors, cannabinoid receptors, and potassium channels, face the same timeline. The conotoxin field is a long-term investment in the pharmacological diversity of nature, not a source of rapid drug approvals.
What has changed is the speed at which new candidates can be identified. Where Olivera's team spent years isolating and characterizing individual peptides from milked venom, modern proteomics and transcriptomics can catalog hundreds of conotoxins from a single species in weeks. Machine learning then prioritizes the most promising candidates for synthesis and testing. The bottleneck has shifted from discovery to delivery, and solving delivery is the challenge that will determine whether the conotoxin revolution produces one approved drug or dozens.
The Bottom Line
Cone snails produce over a million unique venom peptides across approximately 800 species, of which less than 0.1% have been characterized. One conotoxin (omega-MVIIA from Conus magus) became ziconotide, an FDA-approved non-opioid analgesic 1,000 times more potent than morphine. Recent research has expanded conotoxin targets beyond ion channels to include somatostatin receptors, cannabinoid receptors, and antimicrobial applications. Machine learning and proteomic tools are accelerating discovery, but the fundamental challenge of delivery (oral bioavailability, blood-brain barrier crossing) remains the primary barrier to broader clinical translation.